Core Insights - Gilead is experiencing a significant year with the launch of Yeztugo and the completion of the Arcellx deal, indicating a strong focus on expanding its product portfolio [2] - The company reported an extraordinary performance in 2025, highlighted by major product launches and strong financial results, including disciplined operating expense control and significant growth in earnings per share (EPS) [3] Financial Performance - Gilead had two major product launches in 2025: Yeztugo and Livdelzi, which contributed to great financial performance [3] - The company is optimistic about its future, citing the strongest pipeline in its history and the beginning of a long cycle of product launches [3]

Summary of Gilead Sciences FY Conference Call (March 11, 2026) Company Overview - **Company**: Gilead Sciences (NasdaqGS: GILD) - **Key Focus**: Biopharmaceuticals, particularly in oncology and HIV treatment/prevention Core Points and Arguments Financial Performance - Gilead reported an extraordinary performance in 2025, with significant growth in earnings per share (EPS) and strong operating expense control [7] - The company is at the beginning of a long cycle with multiple product launches and the strongest pipeline in its history [7] Product Launches - **Yeztugo**: A once-every-six-month subcutaneous HIV prevention medicine, launched with extraordinary data showing 100% prevention in high-risk populations [23][24] - **Livdelzi**: A drug for liver disease (PBC) that has shown strong initial sales performance [7] - **Anito-cel**: Acquired through a deal with Arcellx for approximately $8 billion, this is a best-in-class BCMA cell therapy for multiple myeloma with a significant commercial opportunity estimated at over $20 billion [9][10] Market Opportunities - The multiple myeloma market is highlighted as a major opportunity, with Gilead's anito-cel showing a differentiated safety profile compared to competitors [11][14] - Gilead's oncology revenues reached approximately $3 billion, representing about 12% of total revenues, with expectations for steady growth in this segment [19][20] Yeztugo Launch Insights - The launch of Yeztugo is tracking well, with $150 million in sales reported for the first year and over 90% payer coverage achieved [24][26] - The company anticipates significant growth, projecting $800 million in sales for the upcoming year, driven by a growing patient base [22][28] Long-term Growth Strategy - Gilead aims to diversify its portfolio beyond HIV, with multiple upcoming product launches across various therapeutic areas, including oncology and liver disease [66][67] - The company has no major patent cliffs until 2036, allowing for sustained growth and investment in its pipeline [67] Challenges and Market Dynamics - The HIV treatment market is expected to shift towards long-acting therapies, with a significant portion of patients currently not diagnosed or not virally suppressed [42][43] - Despite some Medicaid coverage restrictions, Gilead does not foresee a material impact on its business from these changes [46][54] Community Engagement - Gilead is actively working to reach new populations affected by HIV, particularly in underserved communities, through targeted awareness campaigns [61] Additional Important Content - The company is experiencing a shift in the HIV prevention market, with a noted increase in patients starting on Yeztugo who are naive to HIV prevention therapies [25] - Gilead's commercial team is adapting strategies to raise awareness and reduce stigma associated with HIV treatment and prevention [61] - The overall HIV prevention market is expected to grow significantly, with a 50% increase reported from 2024 to 2025 [35][36] This summary encapsulates the key points discussed during the Gilead Sciences FY Conference Call, highlighting the company's financial performance, product launches, market opportunities, and strategic direction.

Core Insights - Jefferies initiated coverage on Gilead Sciences with a Buy rating and a price target of $180, while assigning a Hold rating to Amgen with a target of $350, reflecting differing views on their respective valuations and growth potential [1][2] - JPMorgan maintained an Overweight rating on Oric Pharmaceuticals, emphasizing the unjustified nature of its recent stock pullback due to competitor news [1] Gilead Sciences (GILD) - Jefferies views Gilead as well-positioned due to a clean intellectual property runway until 2036, high operating margins, and the ability to invest in its pipeline while returning capital to shareholders [1] - Gilead reported Q4 2025 revenue of $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, up 2% year-over-year [1] - The company's flagship HIV therapy, Biktarvy, generated $3.97 billion in Q4, while Descovy surged 33% to $819 million [1] Amgen Inc. (AMGN) - Jefferies acknowledged Amgen's strong execution but concluded that a 35% stock run-up has left limited near-term upside, with the stock currently trading above the $350 target [1][2] - Amgen's Q4 revenue was $9.87 billion, surpassing the estimate of $9.66 billion, with a notable growth in Repatha at +44% to $870 million, while Enbrel saw a decline of 48% to $532 million [1] Oric Pharmaceuticals Inc. (ORIC) - JPMorgan's reaffirmation of Oric's Overweight rating comes after a 16.07% drop in shares due to competitor news, which the firm believes does not reflect the fundamentals of Oric's pipeline [1] - Oric's lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer, with a Phase 3 trial initiation expected in H1 2026 [1] - The company holds $392.3 million in cash, projecting a funding runway into the second half of 2028, with shares up 42.42% year-to-date despite recent pullbacks [1]

Core Insights - Jefferies has initiated coverage on Gilead Sciences with a Buy rating and a $180 price target, while assigning a Hold rating to Amgen with a $350 price target, indicating a nuanced view on the biopharma sector [3][5][10] Gilead Sciences - Gilead is positioned as one of the best large-cap biotechs, benefiting from a clean intellectual-property runway until 2036, high operating margins, and overlapping franchises [2][4] - Q4 2025 revenue was $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, reflecting a 2% year-over-year increase [7] - Non-GAAP EPS for Q4 was $1.86, slightly above the estimate of $1.85, and full-year non-GAAP EPS rose significantly to $8.15 from $4.62 in 2024 [7] - The HIV therapy Biktarvy generated $3.97 billion in Q4, up 5%, while Descovy surged 33% to $819 million, with the newly launched Yeztugo expected to be a commercial catalyst [7] - Gilead's stock is currently trading at $146.63, up 19.46% year-to-date, with a forward P/E of 16x reflecting guidance of non-GAAP EPS of $8.45 to $8.85 in 2026 [5][11] Amgen Inc. - Amgen reported Q4 revenue of $9.87 billion, surpassing the estimate of $9.66 billion, with non-GAAP EPS of $5.29, well above the $4.83 estimate [8] - The growth driver was Repatha, which increased by 44% to $870 million, while Enbrel saw a significant decline of 48% to $532 million [8] - Amgen shares are currently trading at $376.97, reflecting a 15.96% year-to-date increase, but are above Jefferies' $350 target, indicating limited near-term upside [5][12] Oric Pharmaceuticals - Oric is a clinical-stage oncology company with no product revenue, but its lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer [9] - The company holds $392.3 million in cash, providing a funding runway into the second half of 2028, despite a recent 16.07% drop in shares due to competitor news [6][9] - The consensus analyst target for Oric is $21.23, while its current price is $11.65, indicating potential upside [9] Analyst Perspectives - Gilead's long IP runway and diversified revenue base, along with a 2.2% dividend yield, make it attractive to income-oriented investors [13] - Amgen's stock has largely priced in strong execution, with risks from biosimilar competition and an unproven obesity pipeline [12][14] - Oric's binary risk nature is highlighted, with significant implications for stock performance based on upcoming clinical data readouts [15]

Core Insights - Gilead Sciences, Inc. is recognized as one of the 13 Best NASDAQ Dividend Stocks to buy currently [1] - Barclays initiated coverage with an Equal Weight rating and set a price target of $155, indicating that the stock's current valuation is considered "rich" [2] Financial Outlook - Gilead's financial outlook for 2026 is conservative, projecting sales of $800 million for Yeztugo, lower than analyst expectations of $907 million [3] - Yeztugo generated $96 million in sales in Q4, surpassing Wall Street estimates of $88 million [3] - The CEO noted a reduction in the 2026 sales growth outlook by about 2 percentage points due to pricing agreements and insurance coverage uncertainties [4] Business Performance - The HIV business showed steady growth, with sales increasing by 6% in 2025, and a similar increase is expected in 2026 [5] - Gilead anticipates adjusted earnings per share between $8.45 and $8.85 for 2026, slightly above the average analyst projection of $8.75 [5] Company Focus - Gilead focuses on developing treatments for serious diseases, including HIV, viral hepatitis, cancer, COVID-19, and inflammatory conditions, with infectious disease treatment being a core aspect of its business [6]

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]

Core Insights - Gilead Sciences, Inc. (GILD) reported strong fourth-quarter and full-year 2025 results, with HIV product sales increasing by 6%, driven by a 7% growth in Biktarvy and a 47% surge in its prevention portfolio [1][2][10] Group 1: HIV Product Performance - Biktarvy holds over 52% market share in the HIV treatment market and is the most prescribed therapy for both treatment-naïve and switch patients [2] - Descovy's sales increased by 31% year over year to $2.8 billion, accounting for more than 45% of the U.S. market share in pre-exposure prophylaxis (PrEP) [3] - The FDA approved injectable lenacapavir (Yeztugo), which offers a twice-yearly dosing schedule, enhancing adherence compared to daily oral regimens [4] Group 2: Financial Projections and Growth Drivers - Despite a $900 million headwind from the Medicare Part D redesign, HIV sales grew 10% when excluding this impact, surpassing management's annual target of 5% growth [2][10] - Gilead expects total HIV sales to grow approximately 6% year over year in 2026, with potential growth of 8% when excluding pricing pressures and channel mix shifts [6] - Early uptake of Yeztugo generated $150 million in 2025, with projected revenues of approximately $800 million in 2026 [5] Group 3: Research and Development Initiatives - Positive phase III results from ARTISTRY-1 and ARTISTRY-2 studies for the investigational BIC/LEN regimen increase the likelihood of regulatory approval, potentially launching by year-end [7] - Gilead is collaborating with Merck to advance its HIV pipeline, with data from studies on islatrovir plus lenacapavir expected in 2026 [8] - Plans to initiate a phase III study evaluating lenacapavir plus broadly neutralizing antibodies are set for the second half of the year [9] Group 4: Competitive Landscape - Gilead faces competition from major players like GSK and Merck in the HIV treatment market, with GSK's growth driven by long-acting injectable medicines [11] - Merck markets doravirine and is evaluating a once-daily oral regimen for treatment-naïve adults with HIV-1 infection [12] Group 5: Stock Performance and Valuation - GILD shares surged 45.9% over the past year, outperforming the industry's growth of 19.6% [15] - The current price/earnings ratio for GILD is 17.46x forward earnings, higher than its historical mean but lower than the large-cap pharma industry average of 18.51x [16]

Group 1 - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a strong investment opportunity by hedge funds, with BofA raising its price target to $162 from $154 while maintaining a Buy rating [1] - The company reported strong fiscal Q4 and full year 2025 results, highlighting the successful launch of Yeztugo, the first twice-yearly HIV prevention therapy, and continued growth in Biktarvy and Descovy [2] - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, driven by higher sales of HIV and Liver Disease products, despite a decline in Veklury® sales [3] Group 2 - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [4]

Core Viewpoint - Gilead Sciences is experiencing strong financial performance and growth potential, particularly in its HIV and liver disease segments, supported by a robust pipeline of new products and an optimistic outlook from analysts [1][2][3][4][6]. Financial Performance - Gilead's Q4 2025 earnings report showed total product sales of $7.9 billion, marking a 5% increase year-over-year [2][6]. - For the full year 2025, total sales reached $28.9 billion, reflecting a 1% increase from 2024 [2][6]. - HIV sales specifically grew by 6% year-over-year, driven by the success of the drug Biktarvy and a 47% increase in the HIV prevention portfolio [2][6]. Product Developments - The new HIV prevention injectable, Yeztugo, has surpassed coverage goals and is gaining market share [3][6]. - Gilead's pipeline includes up to 10 ongoing and potential new launches through 2027, with four commercial launches planned for 2026 [3][6]. - The liver business reported a 6% growth, attributed to the adoption of Livdelzi for primary biliary cholangitis [4][6]. - Trodelvy, an oncology product, also demonstrated positive momentum with a 6% growth in 2025, supported by favorable Phase results [4][6]. Analyst Ratings - BMO Capital has maintained an "Outperform" rating for Gilead, raising the price target from $150 to $160, indicating confidence in the company's future performance [1][6].

Core Viewpoint - Gilead Sciences, Inc. reported strong fourth-quarter results for 2025, with adjusted earnings per share (EPS) of $1.86, exceeding estimates, while total revenues of $7.9 billion also surpassed expectations, driven by growth in HIV and Liver Disease drugs [1][4][6]. Financial Performance - Adjusted EPS for Q4 2025 was $1.86, beating the Zacks Consensus Estimate of $1.83, but down from $1.90 a year ago due to higher acquired IPR&D expenses [1][6]. - Total revenues reached $7.9 billion, a 5% increase year over year, surpassing the Zacks Consensus Estimate of $7.6 billion [1][4]. - Product sales increased by 5% year over year to $7.9 billion, with HIV product sales growing 6% to $5.8 billion [4][5]. Product Sales Breakdown - Biktarvy sales rose 5% year over year to $4 billion, capturing over 52% of the U.S. HIV treatment market [5][6]. - Descovy sales surged 33% year over year to $819 million, driven by increased demand for HIV prevention [6][7]. - Liver Disease portfolio sales increased 17% to $844 million, exceeding estimates, primarily due to demand for Livdelzi [8]. - Veklury sales fell 37% to $212 million, attributed to lower COVID-19 hospitalization rates [8]. Cost and Expenses - Adjusted product gross margin was 86.8%, slightly up from 86.7% year over year [11]. - Research and development expenses remained flat at $1.6 billion, while SG&A expenses decreased to $1.7 billion from $1.9 billion [11][12]. 2025 and 2026 Guidance - For 2025, revenues rose 2% year over year to $29.4 billion, exceeding estimates, with adjusted EPS increasing to $8.15 from $4.62 in 2024 [13]. - Gilead expects 2026 product sales between $29.6 billion and $30 billion, with adjusted EPS projected in the range of $8.45-$8.85 [14][15]. Pipeline and Regulatory Updates - Positive phase III results for the investigational regimen of bictegravir and lenacapavir were reported, with a potential launch targeted for the second half of the year [16][23]. - Gilead has discontinued several studies based on recommendations from independent committees, including the phase III STAR-221 study [18][19]. Market Position and Competitive Landscape - Gilead's HIV business exceeded management's growth target, driven by strong performances from Biktarvy and Descovy, despite competitive pressures [21][22]. - The company anticipates continued competitive pressures in cell therapies and expects to face headwinds from U.S. government drug pricing agreements [24][27].